Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)
Visit JP Morgan's Website
STAY IN TOUCH WITH OUR LATEST NEWS
Subcribe to our newsletter
Copyright 2021 ElsaLys Biotech SA
By continuing to browse this website, you agree to the use of such cookies.